(thirdQuint)Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel.

 This Phase III trial was performed as a monocentric, open label, randomized design, with 1 treatment regimen, in 3 cycles (12 weeks), with administration in multiple doses, in which the healthy volunteers received one coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.

02 mg + 0.

10 mg + 0.

4 mg (Level-Fol(R) Biolab Sanus Farmaceutica, Brazil) for 21 days and a placebo coated tablet containing folic acid 0.

4 mg only (Biolab Sanus Farmaceutica, Brazil) on the last 7 days of the cycle.

 The subjects were required to present to the Clinical Unit for every drug administration, which was assisted by a member of the research team.

 Blood samples of 15 mL were collected via direct venepuncture into tubes containing 50 mu L of ethylenediaminetetraacetic acid (EDTA) at pre-dose, 1st, 21st, 28th, 29th, 49th, 56th, 57th, 77th and 84th day of treatment.

 Te safety assessment was based on recording adverse events throughout the study duration as well as through the monitoring of vital signs and evaluation of laboratory tests and ECG.

.

 Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel@highlight

This trial evaluated folic acid supplementation after oral administration of the ethinyl estradiol + levonorgestrel + folic acid (0.

02 mg + 0.

10 mg + 0.

4 mg) coated tablet (Level-Fol(R) Biolab Sanus Farmaceutica, Sao Paulo, Brazil) in healthy female volunteers, based on statistical comparisons of folate levels in erythrocytes.

 Its safety and tolerability was also evaluated.

